5AM Venture Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

5AM Venture Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-282,313	Closed	-$13.3M	–	26
2025 Q2	$13.3M	Hold	282,313	–	–	5.12%	6
2025 Q1	$11M	Hold	282,313	–	–	4.17%	9
2024 Q4	$15.3M	Hold	282,313	–	–	3.65%	9
2024 Q3	$14.2M	Hold	282,313	–	–	2.94%	16
2024 Q2	$12.4M	Hold	282,313	–	–	2.78%	12
2024 Q1	$14.2M	Sell	282,313 -20,317	-7%	-$1.1M	3.18%	13
2023 Q4	$18.3M	Sell	302,630 -10,580	-3%	-$545K	4.85%	5
2023 Q3	$17.9M	Sell	313,210 -44,276	-12%	-$2.44M	5.14%	5
2023 Q2	$18.2M	Buy	357,486 +318,630	+820%	+$8.57M	4.54%	6
2023 Q1	$831K	Buy	+38,856	New	+$653K	0.21%	24

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

5AM Venture Management's MLTX Position: Q3 2025 in Review

5AM Venture Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 282,313 shares — an estimated $13.3M sold.

5AM Venture Management first reported a position in MLTX in Q1 2023 and held it in 10 quarters. The position peaked at $18.3M in Q4 2023. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

5AM Venture Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
5AM Venture Management sold 282,313 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $13.3M.
5AM Venture Management first reported a position in MoonLake Immunotherapeutics in Q1 2023 and held it in 10 quarters.
5AM Venture Management's MoonLake Immunotherapeutics position peaked at $18.3M in Q4 2023.
134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on 5AM Venture Management's 13F filing for Q3 2025, filed 14 Nov 2025.